SLC5A2 and type 2 diabetes mellitus: However, data from EMPA‐HEART (Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease), which demonstrated significant improvements in LVM following SGLT2 inhibition, found that these changes were independent of systemic blood pressure changes.28